Phase 3 OlympiA clinical trial for Olaparib has demonstrated that patients with germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants could obtain a benefit in early breast cancer [43]. This evidence concerns the gene BRCA1 and breast cancer.